Quality-of-life outcomes in long-term survivors of advanced prostate cancer.
The authors evaluate the temporal progression of health-related quality of life (HRQOL) in men treated hormonally with surgical or medical castration, as well as to see if either treatment would be associated with a greater impact on patients' quality of life. The authors assessed general and prostate-targeted HRQOL with two self-administered, validated instruments (the RAND 36-Item Health Survey and the UCLA Prostate Cancer Index) in a longitudinal, observational study of 63 men newly diagnosed with metastatic prostate cancer and treated with bilateral orchiectomy or combined androgen blockade with leuprolide and flutamide. Patients completed the two HRQOL instruments by mail at baseline and at 3- and 6-month intervals after initiation of treatment. Significant improvements were demonstrated in 10 of 14 HRQOL domains for all men during the first 12 months. These include all eight of the general HRQOL domains and the disease-specific domains that address bowel function. The authors identified no differences in any of the general or prostate-targeted HRQOL domains when comparing men who underwent orchiectomy versus combined androgen blockade. Patients with metastatic prostate cancer can be informed that general and prostate-specific HRQOL will be similar, regardless of whether they choose medical or surgical castration, and that health status will likely remain stable or improve during the initial months of treatment. Physicians must make patients aware of both the quantity and quality of life they can expect with advanced prostate cancer, and must actively involve them in their treatment decisions.
Litwin
M S
MS
Department of Urology, School of Medicine, University of California, Los Angeles 90095-1738, USA.
Shpall
A I
AI
Dorey
F
F
Nguyen
T H
TH
D000368:Aged; D018931:Antineoplastic Agents, Hormonal; D003657:Decision Making; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D010358:Patient Participation; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D018434:Sickness Impact Profile; D017741:Survivors
D018931:Antineoplastic Agents, Hormonal